|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2
|
Zisman A, Pantuck AJ, Wieder J, et al:
Risk group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finley DS, Pantuck AJ and Belldegrun AS:
Tumor biology and prognostic factors in renal cell carcinoma.
Oncologist. 16(Suppl 2): 4–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phuoc NB, Ehara H, Gotoh T, et al:
Prognostic value of the co-expression of carbonic anhydrase IX and
vascular endothelial growth factor in patients with clear cell
renal cell carcinoma. Oncol Rep. 20:525–530. 2008.PubMed/NCBI
|
|
6
|
Girgin C, Tarhan H, Hekimgil M, Sezer A
and Gurel G: P53 mutations and other prognostic factors of renal
cell carcinoma. Urol Int. 66:78–83. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klatte T, Seligson DB, Riggs SB, et al:
Hypoxia-inducible factor 1 alpha in clear cell renal cell
carcinoma. Clin Cancer Res. 13:7388–7393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS and
Kim SI: Prognostic significance of preoperative C-reactive protein
elevation and thrombocytosis in patients with non-metastatic renal
cell carcinoma. Korean J Urol. 52:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao M, Yoshida M, Kishida T, et al: VHL
tumor suppressor gene alterations associated with good prognosis in
sporadic clear-cell renal carcinoma. J Natl Cancer Inst.
94:1569–1575. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dahl CA, Schall RP, He HL and Cairns JS:
Identification of a novel gene expressed in activated natural
killer cells and T cells. J Immunol. 148:597–603. 1992.PubMed/NCBI
|
|
11
|
Kim SH, Han SY, Azam T, Yoon DY and
Dinarello CA: Interleukin-32: A cytokine and inducer of TNF alpha.
Immunity. 22:131–142. 2005.PubMed/NCBI
|
|
12
|
Chen Q, Carroll HP and Gadina M: The
newest interleukins: recent additions to the ever-growing cytokine
family. Vitam Horm. 74:207–228. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Csernok E, Holle JU and Gross WL:
Proteinase 3, protease-activated receptor-2 and interleukin-32:
linking innate and autoimmunity in Wegener’s granulomatosis. Clin
Exp Rheumatol. 26:S112–S117. 2008.PubMed/NCBI
|
|
14
|
Joosten LA, Netea MG, Kim SH, et al:
IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc
Natl Acad Sci USA. 103:3298–3303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Netea MG, Azam T, Lewis EC, et al:
Mycobacterium tuberculosis induces interleukin-32 production
through a caspase-1/IL-18/interferon-gamma-dependent mechanism.
PLoS Med. 3:e2772006. View Article : Google Scholar
|
|
16
|
Shioya M, Nishida A, Yagi Y, et al:
Epithelial overexpression of interleukin-32alpha in inflammatory
bowel disease. Clin Exp Immunol. 149:480–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seo EH, Kang J, Kim KH, et al: Detection
of expressed IL-32 in human stomach cancer using ELISA and
immunostaining. J Microbiol Biotechnol. 18:1606–1612.
2008.PubMed/NCBI
|
|
18
|
Sorrentino C and Di Carlo E: Expression of
IL-32 in human lung cancer is related to the histotype and
metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishida A, Andoh A, Inatomi O and Fujiyama
Y: Interleukin-32 expression in the pancreas. J Biol Chem.
284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marcondes AM, Mhyre AJ, Stirewalt DL, Kim
SH, Dinarello CA and Deeg HJ: Dysregulation of IL-32 in
myelodysplastic syndrome and chronic myelomonocytic leukemia
modulates apoptosis and impairs NK function. Proc Natl Acad Sci
USA. 105:2865–2870. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ko NY, Chang SH, Lee JH, et al: Unique
expression of a small IL-32 protein in the Jurkat leukemic T cell
line. Cytokine. 42:121–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee S, Kim JH, Kim H, et al: Activation of
the interleukin-32 pro-inflammatory pathway in response to human
papillomavirus infection and over-expression of interleukin-32
controls the expression of the human papillomavirus oncogene.
Immunology. 132:410–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carter KL, Cahir-McFarland E and Kieff E:
Epstein-Barr virus-induced changes in B-lymphocyte gene expression.
J Virol. 76:10427–10436. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park GH, Choe J, Choo HJ, Park YG, Sohn J
and Kim M: Genome-wide expression profiling of
8-chloroadenosine-and 8-chloro-cAMP-treated human neuroblastoma
cells using radioactive human cDNA microarray. Exp Mol Med.
34:184–193. 2002. View Article : Google Scholar
|
|
25
|
Goda C, Kanaji T, Kanaji S, et al:
Involvement of IL-32 in activation-induced cell death in T cells.
Int Immunol. 18:233–240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Netea MG, Azam T, Ferwerda G, et al: IL-32
synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2
ligands for IL-1beta and IL-6 production through a caspase
1-dependent mechanism. Proc Natl Acad Sci USA. 102:16309–16314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klatte T, Pantuck AJ, Kleid MD and
Belldegrun AS: Understanding the natural biology of kidney cancer:
implications for targeted cancer therapy. Rev Urol. 9:47–56.
2007.PubMed/NCBI
|
|
28
|
Delahunt B, Kittelson JM, McCredie MR,
Reeve AE, Stewart JH and Bilous AM: Prognostic importance of tumor
size for localized conventional (clear cell) renal cell carcinoma:
assessment of TNM T1 and T2 tumor categories and comparison with
other prognostic parameters. Cancer. 94:658–664. 2002. View Article : Google Scholar
|
|
29
|
Terrone C, Gontero P, Volpe A, et al:
Proposal of an improved prognostic classification for pT3 renal
cell carcinoma. J Urol. 180:72–78. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eble JN, Sauter G, Ebstein J and
Sesterhenn I: Pathology and Genetics of Tumours of the Urinary
System and Male Genital Organs. IARC-Press; Lyon: 2004
|
|
31
|
Ficarra V, Schips L, Guille F, et al:
Multiinstitutional European validation of the 2002 TNM staging
system in conventional and papillary localized renal cell
carcinoma. Cancer. 104:968–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Delahunt B, Sika-Paotonu D, Bethwaite PB,
et al: Fuhrman grading is not appropriate for chromophobe renal
cell carcinoma. Am J Surg Pathol. 31:957–960. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheville JC, Lohse CM, Zincke H, Weaver AL
and Blute ML: Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma. Am J Surg Pathol.
27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Patard JJ, Leray E, Rioux-Leclercq N, et
al: Prognostic value of histologic subtypes in renal cell
carcinoma: a multicenter experience. J Clin Oncol. 23:2763–2771.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee SE, Byun SS, Oh JK, et al:
Significance of macroscopic tumor necrosis as a prognostic
indicator for renal cell carcinoma. J Urol. 176:1332–1337. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim HL, Belldegrun AS, Freitas DG, et al:
Paraneoplastic signs and symptoms of renal cell carcinoma:
implications for prognosis. J Urol. 170:1742–1746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leibovich BC, Sheinin Y, Lohse CM, et al:
Carbonic anhydrase IX is not an independent predictor of outcome
for patients with clear cell renal cell carcinoma. J Clin Oncol.
25:4757–4764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oh J, Cho M, Kim J, et al: IL-32γ inhibits
cancer cell growth through inactivation of NF-κB and STAT3 signals.
Oncogene. 2011.(E-pub ahead of print).
|
